Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-2: talazoparib with enzalutamide in metastatic castration-resistant prostate cancer
2023-509087-20-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Talazoparib + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoints: Occurrence of target safety events, BICR-assessed radiographic progression-free survival in mCRPC unselected for DDR status and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
talazoparibenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-509087-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509087-20-00.